Dr. Beth Israel Deaconess Medical Center/Harvard Medical School, United States
Dimitrios Farmakiotis, MD, FACP, FIDSA, is a leading expert in transplant and oncology infectious diseases, currently serving as an Attending at Beth Israel Deaconess Medical Center and Associate Professor at Brown University. He specializes in infectious complications in immunocompromised patients, with a focus on fungal infections and antimicrobial stewardship. Dr. Farmakiotis has held academic and clinical roles at Harvard Medical School, Brigham and Women’s Hospital, Dana-Farber Cancer Institute, and Baylor College of Medicine. His extensive research contributions, invited lectures, and leadership in professional societies have earned him numerous accolades. He serves on prestigious panels, including the IDSA and the COVID-19 & Cancer Consortium. A dedicated educator, he mentors future infectious disease specialists while advancing clinical practice through groundbreaking studies.
Publication Profile
Google Scholar
Education 🎓
Dr. Farmakiotis graduated as Valedictorian from Anatolia College of Thessaloniki (1996) and earned his MD from Aristotle University of Thessaloniki (2002) with top honors (GPA 92.1/100). His postgraduate training includes a rural medical practice in Greece (2003-2004), Internal Medicine residency at the Infectious Diseases Hospital of Thessaloniki (2005-2007), and at Albert Einstein College of Medicine (2008-2011). He completed an Infectious Diseases fellowship at Baylor College of Medicine (2011-2014) and an advanced Transplant-Oncology Infectious Diseases fellowship at Brigham and Women’s Hospital and Dana-Farber Cancer Institute, Harvard Medical School (2014-2015). His education reflects a commitment to excellence in patient care, research, and medical education.
Experience 💼
Dr. Farmakiotis has extensive experience in infectious disease management, focusing on immunocompromised hosts. He was Chief Fellow at Baylor College of Medicine (2012-2013), followed by faculty roles at Brown University’s Division of Infectious Diseases. He has been an Attending Physician in transplant and oncology infectious diseases at Beth Israel Deaconess Medical Center, with a pending Harvard Medical School appointment. He has served as an Institutional Review Board (IRB) member at Brown University and contributed to international guidelines on immunomodulatory therapy-related infections. His expertise extends to leading clinical research initiatives, mentoring medical residents, and advancing infectious disease treatment protocols
Awards and Honors 🏆
Dr. Farmakiotis has received numerous prestigious awards, including the AECOM Leo M. Davidoff Award (2010, 2011), IDSA Mentorship Program Awards (2016, 2017), and the Thomas J. Walsh Young Investigator Award (2016). He has won multiple research presentation awards at IDWeek, ICAAC, and the American College of Physicians. His work has been featured in UpToDate, Reuters Health, and CDC press releases. He was awarded permanent US residency under the “Scientist of Extraordinary Ability” category (2014). He received the IDWeek Kass Award for a top trainee abstract (2021) and leadership recognition at Brown Physicians Inc. Leadership Academy (2023).
Research Focus 🧬
Dr. Farmakiotis specializes in transplant and oncology infectious diseases, with a focus on fungal infections, antimicrobial stewardship, and immunocompromised host infections. His research explores novel antifungal therapies, drug resistance mechanisms, and optimal infection control strategies in high-risk patients. He has contributed to major IDSA guidelines and led clinical studies on fungal diagnostics, antimicrobial resistance, and immunosuppressive therapy complications. His work has shaped best practices in treating infections in cancer and transplant patients, earning him recognition in peer-reviewed journals, national conferences, and professional panels.
Publication Top Notes
1️⃣ CMV T-cell Immunity Panel (TCIP)-Guided Secondary CMV Prophylaxis Duration in Lung Transplant Recipients (2025)
Authors: AE Franceschi Coll, MA Diaz, H Alshaker, J Safiia, DG Moshovitis, D Farmakiotis
Citation: Open Forum Infectious Diseases 12 (Supplement_1), ofae631. 2324
2️⃣ Clinical Utility of Cell-free Next-generation Sequencing, Single Center Experience (2025)
Authors: O Ibrahim, R Rogers, D Farmakiotis
Citation: Open Forum Infectious Diseases 12 (Supplement_1), ofae631. 2321
3️⃣ Antimicrobial Resistance among Gram-negative Urinary Isolates from Kidney Transplant Recipients: Implications for Precision Antimicrobial Stewardship (2025)
Authors: A London, D Farmakiotis, KM Vieira, R Rogers, Y Shi
Citation: Open Forum Infectious Diseases 12 (Supplement_1), ofae631. 1732
4️⃣ Correction: Diet Modification and Metformin Have a Beneficial Effect in a Fly Model of Obesity and Mucormycosis (2025)
Authors: F Shirazi, D Farmakiotis, Y Yan, N Albert, D Kim-Anh, DP Kontoyiannis
Citation: PloS One 20 (1), e0317530
5️⃣ Perceptions of COVID-19 Vaccination among Organ Transplant Recipients (2024)
Authors: R Lerner, P Arvanitis, D Guermazi, D Farmakiotis
Citation: Transplantation Proceedings 56 (8), 1861-1869
6️⃣ Medical Malpractice in Organ Transplantation: Public Allegations and Key Legal Outcomes (2024)
Authors: P Arvanitis, MR Davis, A London, D Farmakiotis
Citation: Frontiers in Health Services 4, 1408934
7️⃣ The Impact of Cancer Metastases on COVID‐19 Outcomes: A COVID‐19 and Cancer Consortium Registry‐Based Retrospective Cohort Study (2024)
Authors: CA Castellano, T Sun, D Ravindranathan, C Hwang, N Balanchivadze, D Farmakiotis
Citation: Cancer 130 (12), 2191-2204
8️⃣ Progressive Multifocal Leukoencephalopathy Unmasked by Teclistamab in a Refractory Multiple Myeloma Patient (2024)
Authors: P Arvanitis, D Farmakiotis, A Pelcovits
Citation: Current Oncology 31 (5), 2670-2678
9️⃣ Using a Commercially Available Assay That Measures Cytomegalovirus (CMV)-Specific CD4+ and CD8+ T-cell Immunity to Predict Protection Against CMV (2023)
Authors: NK Almaghlouth, P Arvanitis, K Vieira, D Farmakiotis
Citation: Open Forum Infectious Diseases 10 (Supplement_2), ofad500. 697
🔟 Nirmatrelvir/Ritonavir Use Among Patients with Cancer and COVID-19 is Associated with Improved Clinical Outcomes: Single-Institution Case-Control Study (2023)
Authors: P Arvanitis, K Vieira, JL Warner, D Farmakiotis
Citation: Open Forum Infectious Diseases 10 (Supplement_2), ofad500. 577
Conclusion
Dr. Farmakiotis is an exceptional candidate for the Best Researcher Award, given his high-impact research, clinical expertise, mentorship, and leadership roles. While he could expand into broader infectious disease research and secure more independent funding, his current contributions and recognitions make him a strong contender for this award.